Severe eosinophilic asthma — RCPSC IM MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Add a biologic targeting type 2 inflammation after confirming phenotype and access criteria
Frequent exacerbations despite optimized high-dose inhaled therapy with eosinophilia support severe type 2 asthma; biologic therapy should be considered after confirming phenotype, adherence and comorbidities.
Reference: Canadian Thoracic Society severe asthma guidance